Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in severe persistent asthma
NCT02443298Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2015
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of risankizumab in severe asthma, sponsored by AbbVie Inc.. Started Jun 2015; status: completed.
02
Drugs
risankizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT02443298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443298.